 Having now proven its drug works on two eye diseases, Opthea ASX:OPT is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema DME, similar to its planned phase three study in wet-AMD. The company will spend the next few months planning the DME study but the wet-AMD ... 